Sapu Nano Expands Sapu003 Trials Globally, Taps GCT as Lead CRO
Event summary
- Sapu Nano and Oncotelic Therapeutics have expanded the Phase 1b clinical trial of Sapu003 (Everolimus for Injection) internationally, appointing Global Clinical Trials (GCT) as the lead CRO.
- The SP-03-B101 study will now include sites in Europe, building on its initial Australian footprint.
- GCT was selected for its oncology expertise, regulatory capabilities, and global logistics infrastructure.
- Sapu003 is a proprietary intravenous formulation of everolimus, developed using Sapu Nano's Deciparticle™ platform technology.
The big picture
Sapu Nano's move to internationalize Sapu003's Phase 1b trials reflects a broader trend in oncology drug development, where early global engagement is seen as critical for accelerating regulatory approvals and market access. The appointment of GCT underscores the growing reliance on specialized CROs to manage complex, multinational clinical operations. Oncotelic Therapeutics' strategy aligns with its goal of leveraging its proprietary Deciparticle™ platform to differentiate Sapu003 in a competitive mTOR inhibitor landscape.
What we're watching
- Regulatory Momentum
- Whether the accelerated regulatory submissions by GCT signal smoother global approval pathways for Sapu003.
- Execution Risk
- The pace at which Sapu Nano can scale its international clinical network while maintaining data consistency.
- Strategic Positioning
- How early multinational Phase 1b expansion will impact the efficiency of future Phase 3 registrational studies.
Related topics